Protagonist Therapeutics, Inc. (PTGX)
Automate Your Wheel Strategy on PTGX
With Tiblio's Option Bot, you can configure your own wheel strategy including PTGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTGX
- Rev/Share 3.3003
- Book/Share 10.9436
- PB 4.9271
- Debt/Equity 0.0165
- CurrentRatio 17.2551
- ROIC 0.0378
- MktCap 3342069440.0
- FreeCF/Share 5.3251
- PFCF 9.9678
- PE 60.4169
- Debt/Assets 0.0153
- DivYield 0
- ROE 0.0922
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PTGX | Citigroup | -- | Buy | -- | $72 | June 17, 2025 |
| Initiation | PTGX | BMO Capital Markets | -- | Outperform | -- | $62 | Dec. 6, 2024 |
| Initiation | PTGX | Goldman | -- | Neutral | -- | $47 | Dec. 6, 2024 |
| Initiation | PTGX | TD Cowen | -- | Buy | -- | $65 | Sept. 24, 2024 |
| Initiation | PTGX | Truist | -- | Buy | -- | $60 | Sept. 9, 2024 |
News
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity program enhance Protagonist's strategic value and acquisition appeal.
Read More
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Read More
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Read More
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Read More
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Published: March 10, 2025 by: Investors Business Daily
Sentiment: Positive
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
Read More
About Protagonist Therapeutics, Inc. (PTGX)
- IPO Date 2016-08-11
- Website https://www.protagonist-inc.com
- Industry Biotechnology
- CEO Dr. Dinesh V. Patel Ph.D.
- Employees 124